JOIN US VIRTUALLY

Guardant Health at AACR

Annual Meeting 2021

LEARN MORE

Week 1: April 10-15
Week 2: May 17-21

Conquering Cancer Through Data

Leading precision oncology company Guardant Health will present data on its liquid biopsy technology, including any particular data or study or test to hightlight, at the 2021 virtual AACR Annual Meeting. 

More than XX presentations and posters, now online, demonstarte the value of liquid biopsy in advancing precision oncology across the cancer continuum.

Delivering the Promise of Precision Oncology Across the Continuum of Care

Guardant Health, along with leading academic institutions and pharmaceutical companies, will present exciting new data at the AACR Annual Meeting 2021 that further highlight the growing clinical utility of liquid biopsy.

Live streamed oral presentations
Late-breaking abstracts
Poster presentations

Key Abstracts

Findings demonstrate the value of Guardant Health’s liquid biopsy tests in detecting actionable mutations, informing treatment decisions, and revealing tumor evolution and resistance in response to therapy, including immunotherapies.
April 10 | 2:20 PM – 2:30 PM EST

Session MS.CL01.01 – Biomarkers

Mini-Symposium


Guardant360®
April 10 | 8:30 AM – 11:59 PM EST

Session PO.CT02 –
Phase II Clinical Trials

Poster


Guardant360® CDx
April 10 | 8:30 AM – 11:59 PM EST

Session PO.CL11.01 – Biomarkers Predictive of Therapeutic Benefit

Poster


Guardant360®
GuardantOMNI® 
  • 401 – Comparison of molecular response calculations for prediction of patient outcome

    Presenter/First Author: Allysia J. Mak; Guardant Health

April 10 | 8:30 AM – 11:59 PM EST

Session PO.CL11.04 – Liquid Biopsies:
Circulating DNA

Poster


Guardant360®
Guardant360® CDx
GuardantOMNI® 
Data on Guardant Health’s proprietary blood tests were featured in more than XX presentations and posters, including a live-streamed oral presentation and panel discussion. View key abstracts below.

25 - Reversion patterns in homologous recombination repair genes in metastatic cancer patients profiled by cell-free DNA

April 10, 2021 | 2:20 PM – 2:30 PM
Session MS.CL01.01 – Biomarkers | Mini-Symposium

Presenter/Author: Fu Y, Yen J, Yu Fu, Aartyomenko A et al.

View Abstract

Breaking Abstract - Clinical validation of plasma cell-free DNA (cfDNA) sequencing in the phase 2 trial of sotorasib in patients (pts) with KRAS p.G12C mutated NSCLC

TBD | Poster | Session PO.CL11.04 – Liquid Biopsies: Circulating DN

Author TBD

View Abstract

401 - Comparison of molecular response calculations for prediction of patient outcome

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.01 – Biomarkers Predictive of Therapeutic Benefit | Poster

Presenter/Author: Mak AJ, Quinn KJ, Espenschied C et al.

View Abstract

LB054 - Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.04 – Liquid Biopsies: Circulating DNA | Poster

Presenter/Author: Hayes JL,  Koczywas M, Ou SI et al.

View Abstract

537 - NTRK1 fusion detection from clinical cfDNA NGS using a de novo fusion caller

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.04 – Liquid Biopsies: Circulating DNA | Poster

Presenter/Author: Yablonovitch A,  Gnerre S, Jennifer Yen et al.

View Abstract

571 - Detection of somatic copy number alterations from on-target and off-target sequencing data

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.04 – Liquid Biopsies: Circulating DNA | Poster

Author: Catalin Barbacioru

View Abstract

572 - The liquid biopsy Guardant360 CDx has robust performance at low inputs allowing for high rate of returning patient results

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.04 – Liquid Biopsies: Circulating DNA | Poster

Presenter/Author: Richardson AO,  Hardin A,  Shukla S et al.

View Abstract

576 - A single institution experience with Guardant360 liquid biopsy for therapeutic decision in advanced solid tumors

April 10, 2021 | 8:30 AM – 11:59 PM
Session PO.CL11.04 – Liquid Biopsies: Circulating DNA | Poster

Presenter/Author: Murad AM,  Casali da Rocha JC.  

View Abstract

Transforming Cancer Care Through Liquid Biopsy

Guardant Health’s portfolio of liquid biopsies, provide valuable insights that have a meaningful impact on patients at all stages of the disease.

Treatment Selection

Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling of advanced cancer patients across all solid tumors. The test is also a companion diagnostic to identify patients who may benefit from Tagrisso® (osimertinib).

Guideline-complete genomic profiling results to inform 1L treatment plans

Covered by Medicare for patients with newly-diagnosed or treatment-refractory advanced solid tumors

Results in 7 days—including matched therapies and trials—in a simple, easy-to-use format

Residual Disease and Recurrence Monitoring

Guardant Reveal™ is the first blood-only liquid biopsy for residual disease detection and recurrence monitoring. It is commercially available for use in early-stage colorectal cancer (CRC), with additional cancer types to follow.

Results reported in as few as 7 days for faster time to treatment and easier surveillance

Identifies patients at the highest risk of recurrence who may benefit most from adjuvant chemotherapy and active surveillance

Detects recurrent disease months earlier than current standard of care methods (e.g. imaging or carcinoembryonic antigen)

Screening

The LUNAR-2 liquid biopsy is a multi-cancer blood test for early detection of cancer in screen-eligible asymptomatic adults.

The 10,000 patient ECLIPSE study, one of the largest cancer screening studies of its kind, is currently evaluating LUNAR-2 in detecting early-stage CRC

LUNAR-2 has demonstrated high sensitivity and specificity in detecting CRC, our first indication for early cancer detection¹

Trial is expected to complete enrollment by year end, and if successful, support submission to the FDA

Want to find out more about our portfolio of products?
Learn more

Actionable Insights Across the Cancer Continuum

A portfolio of complete genomic profiling assays provides…  


Treatment Selection

Guardant360 CDx liquid biopsy provides complete genomic profiling results in 7 days. Guardant360 CDx liquid biopsy provides complete genomic profiling results in 7 days. Guardant360 CDx liquid biopsy provides complete genomic profiling results in 7 days. Guardant360 CDx liquid biopsy provides complete genomic profiling results in 7 days.


Recurrence Monitoring

GuardantREVEAL is the first blood-only test for residual disease detection and recurrance monitoring. With results reported in as few as 7 days, GuardantREVEAL identifies your patients at the highest risk of recurrence without the hassle and delays of tissue testing and detects recurrent disease months earlier than current standard of care methods (i.e. imaging or CEA).


Screening

LUNAR-2 detects early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw. LUNAR-2 detects early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw. LUNAR-2 detects early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw. LUNAR-2 detects early-stage cancer in screen-eligible 

Recent News

View our latest press releases

  1. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology. 2019;30(7):1121-1126.

Helping people enhance their wealth

Exponent WordPress theme is insanely flexible and amazingly easy to use. This alone would be enough for a 5 star rating. On top of a great tool is even better customer support. The only theme you will ever need.

Google Maps API KEY is missing

A simple blood draw helps patients get the right drug. 

Soon, it could detect cancer earlier than ever before.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound